Welcome To Recro Pharma
Recro Pharma, Inc. is a revenue generating specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially for acute post operative pain.
Recro Pharma has two product candidates in mid to late stage clinical trials for the management of acute post operative pain. IV/IM meloxicam, a proprietary, long-acting preferential COX-2 inhibitor has successfully completed multiple Phase II clinical trials and is ready to begin pivotal Phase III clinical trials. We believe IV/IM meloxicam compares favorably to competitive therapies in magnitude of pain relief, onset of pain relief, duration of pain relief and time to peak analgesic effect.
Dex-IN, a proprietary intranasal formulation of dexmedetomidine, is currently being tested in Phase II clinical trials. Dexmedetomidine, or Dex, is a selective alpha-2 adrenergic agonist that has demonstrated sedative, analgesic and anxiolytic properties. If approved, Dex-IN would also be the first and only approved acute post operative pain drug in its class of drugs.
Recro Pharma owns and operates an 87,000 square foot, DEA-licensed facility that manufactures five commercial products which are commercialized by partners, and receives royalties associated with the sales of these products.